Review Article

Serpin Inhibition Mechanism: A Delicate Balance between Native Metastable State and Polymerization

Mohammad Sazzad Khan,1 Poonam Singh,1 Asim Azhar,1 Asma Naseem,1 Qudsia Rashid,1 Mohammad Anaul Kabir,2 and Mohamad Aman Jairajpuri1

1Department of Biosciences, Jamia Millia Islamia University, Jamia Nagar, New Delhi 110025, India
2Department of Biotechnology, National Institute of Technology Calicut (NITC), NIT Campus P.O., Calicut, Kerala 673601, India

Correspondence should be addressed to Mohamad Aman Jairajpuri, mjairajpuri.bi@jmi.ac.in

Received 14 February 2011; Accepted 7 March 2011

Academic Editor: Zulfiqar Ahmad

Copyright © 2011 Mohammad Sazzad Khan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The serpins (serine proteinase inhibitors) are structurally similar but functionally diverse proteins that fold into a conserved structure and employ a unique suicide substrate-like inhibitory mechanism. Serpins play absolutely critical role in the control of proteases involved in the inflammatory, complement, coagulation and fibrinolytic pathways and are associated with many conformational diseases. Serpin’s native state is a metastable state which transforms to a more stable state during its inhibitory mechanism. Serpin in the native form is in the stressed (S) conformation that undergoes a transition to a relaxed (R) conformation for the protease inhibition. During this transition the region called as reactive center loop which interacts with target proteases, inserts itself into the center of β-sheet A to form an extra strand. Serpin is delicately balanced to perform its function with many critical residues involved in maintaining metastability. However due to its typical mechanism of inhibition, naturally occurring serpin variants produces conformational instability that allows insertion of RCL of one molecule into the β-sheet A of another to form a loop-sheet linkage leading to its polymerization and aggregation. Thus understanding the molecular basis and amino acid involved in serpin polymerization mechanism is critical to devising strategies for its cure.

1. Introduction

Serpins (serine proteinase inhibitors) are the largest super family of protease inhibitors involved in many critical biological processes like blood coagulation, fibrinolysis, programmed cell death, development and inflammation [1–3]. Serpins are structurally heterogeneous and functionally diverse proteins found in the organisms ranging from viruses to vertebrates [4–6]. Over 400 different serpins have been identified in organisms including viruses, plants, insects, animals and prokaryotes [7]. Serpins like α-antitrypsin, α-antichymotrypsin, C1-inhibitors, antithrombin, and plasminogen activator inhibitor-1 (PAI), play absolutely critical role in the control of proteases involved in the inflammatory, complement, coagulation and fibrinolytic pathways, respectively, and are associated with diseases like emphysema/cirrhosis, angioedema, familial dementia, chronic obstructive bronchitis and thrombosis [8]. Not all serpins act as protease inhibitors some are inhibitors of other types of proteinases, while others are noninhibitors. For example, the viral serpin crmA inhibits interleukin-1 converting enzyme and squamous cell carcinoma, antigen-1 (SCCA-1) inhibits cysteine proteinases of the papain family. Noninhibitory serpins perform diverse functions, including roles as chaperones, for example, the 47-kD heat shock protein [HSP47] and hormone transportation like cortisol-binding globulin [7].

2. Serpin Structure and Common Mechanism of Action

There is a high rate of conservation in the structure among the members of serpin family in which the average size of
protein is 350–400 amino acids and the molecular weight of 40–50 kDa [4]. The serpin fold is comprised of 3-β sheets (A, B, C) and 7–9 alpha helices. A solvent exposed stretch of amino acids termed as reactive centre loop (RCL) contains the protein recognition site which forms a flexible stretch of ∼17 residues between β sheets A and C [8]. The mechanism of inhibition of serpin has been demonstrated biophysically and structurally as suicide substrate-like inhibitory mechanism (as shown in Figure 1) where after binding to protease it is partitioned between cleaved serpin and serpin-protease complex [9]. Initially serpin binds to protease through a noncovalent Michaelis-like complex by interactions with residues flanking the scissile bond (P1-P1′) [6]. Attack of the active site serine on the scissile bond leads to a covalent ester linkage between Ser-195 of the protease and the backbone carbonyl of the P1 residue resulting in the cleavage of the peptide bond. Protease specificity is determined by the P1-P1′ bond which is positioned such that it is readily accessible to proteases, Table 1 shows the residues involved in P1-P1′ in various serpins. RCL inserts into the β sheet A and transports the covalently bound protease with it. As a result protease gets translocated by over 70 Å (Figure 1) and its active site gets distorted [6, 8]. Distortion of the active site prevents the final hydrolysis events and the result is an irreversible covalent serpin-enzyme complex. When active serpins are proteolytically inactivated in a substrate-like reaction, they undergo an important structural transition with a resultant increase in their conformation stability [9]. The P4-P4′ sequence of RCL is highly conserved in all inhibitory serpins and mutations in this region (P2 Gly to Pro mutation in antithrombin) result in loss of inhibitory activity [12]. In antithrombin the replacement of P12 Ala by the Thr causes loss of inhibitory activity which is due to polymerization of antithrombin [13]. The breach region represents the point of initial insertion of the RCL which is located at the top of the A β-sheet [14]. Near the centre of A β-sheet is the shutter domain [15]. The breach and shutter are two major regions that assist sheet opening and accept the conserved hinge of the RCL when it inserts [8]. Highly conserved residues located in the shutter region of the β-sheet A of the serpin fold are Ser-53 and Ser-56 which play an important role in the serpin conformational transitions [16]. The gate region is composed of s3C and s4C strands which has been primarily observed by studies of the transition of active PAI-1 into latency [17]. In order to insert fully into the A β-sheet

Figure 1: The scheme shown here (taking antithrombin as an example) represents the suicide substrate inhibition mechanism common to all inhibitory serpins. The scheme represents the interaction between the serpin (antithrombin, ATIII) and protease (E); ATIII-E is the noncovalent Michaelis complex; ATIII-E’ is the proposed intermediate before partitioning; ATIII-E∗ is the stable protease-inhibitor complex; ATIII∗ is the cleaved ATIII. The outcome of the reaction is dependent on the partitioning between the inhibitory (k_inh) and substrate pathways (k_sub). The figures represent the cleaved and factor Xa bound ternary complexes of antithrombin [3].

3. Domains Involved in Serpin Inhibition Mechanism

Several regions are important in controlling and modulating serpin conformational changes; Figure 2 shows functionally and structurally important regions of serpin [10]. A portion of RCL from P15–P9 is called the hinge region [3, 11]. In S → R transition it provides mobility which is vital for the conformational change of the RCL. Hinge region contains many conserved residues between P15–P10, towards the N-terminal of the RCL. Out of these the amino acid at P14 (Ser-380) is of critical importance as its insertion in the β-sheet A is a prerequisite for inhibitory activity [12]. In antithrombin the replacement of P12 Ala by the Thr causes loss of inhibitory activity which is due to polymerization of antithrombin [13]. The breach region represents the point of initial insertion of the RCL which is located at the top of the A β-sheet [14]. Near the centre of A β-sheet is the shutter domain [15]. The breach and shutter are two major regions that assist sheet opening and accept the conserved hinge of the RCL when it inserts [8]. Highly conserved residues located in the shutter region of the β-sheet A of the serpin fold are Ser-53 and Ser-56 which play an important role in the serpin conformational transitions [16]. The gate region is composed of s3C and s4C strands which has been primarily observed by studies of the transition of active PAI-1 into latency [17]. In order to insert fully into the A β-sheet
thrombin causes a series of large conformational shifts (as Binding of heparin pentasaccharide to the D helix of antithrombin gets activated. glycosaminoglycan consisting of alternating glucosamine (PN-1) and PAI-1. Heparin is a highly negatively charged the reaction of PAI-1 with thrombin [21]. A subfamily of plex bridging mechanism. Vitronectin also seems to help improved by such ligands in accordance with a ternary com-plex cosaminoglycan ligands have their reactions with proteases upon binding of heparin and other negatively charged serpins exists whose inhibitory activity is greatly accelerated direct contact with the pentasaccharide sequence [23]. It has been shown that mutation of either Phe-121 or Phe-122 leads to decline in antithrombin-heparin binding affinity. Cofactor binding serpins are critically balanced to maintain its native metastability during its binding and transformation of conformational change (Figure 3).

4. Ligand-Dependent Serpins

One of the important features of serpins is their ability to bind various protease and nonprotease ligand (Table 2) and some of the examples of ligand-dependent serpins are antithrombin, heparin cofactor II, protein C inhibitor, plasminogen-activator inhibitor-1 (PAI-1), protease nexin-1 and kallistatin [19]. Binding of ligand to these serpins regulate their activity, like PAI-1 binds to vitronectin or ZPI binds to protein Z [20]. Several serpins which interact with glycosaminoglycan ligands have their reactions with proteases improved by such ligands in accordance with a ternary complex bridging mechanism. Vitronectin also seems to help the reaction of PAI-1 with thrombin [21]. A subfamily of serpins exists whose inhibitory activity is greatly accelerated upon binding of heparin and other negatively charged polyanions, such as heparan sulfate and dermatan sulphate. The members of this group include heparin cofactor II (HCII), antithrombin, protein C inhibitor, protease nexin 1 (PN-1) and PAI-1. Heparin is a highly negatively charged glycosaminoglycan consisting of alternating glucosamine and iduronic acid monomers. Studies have demonstrated that upon binding to heparin antithrombin gets activated. Binding of heparin pentasaccharide to the D helix of anti-thrombin causes a series of large conformational shifts (as shown in Figure 3). Extension of D-helix at both the ends leads to an interdomain rotation of the bottom half of the antithrombin relative to the top half, which leads to RCL expulsion from the β-sheet A and exposure of the P1 arginine (Arg-393) residue [18, 22]. The basic residues in this site that interact with the pentasaccharide are Lys-11 and Arg-13 in the N-terminal end; Arg-46 and Arg-47 in the A-helix; and Lys-114, Lys-125, and Arg-129 in the region of the D-helix (Figure 3). Two nonbasic residues, Phe-121 and Phe-122, reside near these positively charged amino acids of the heparin-binding domain but make minimal direct contact with the pentasaccharide sequence [23]. It has been shown that mutation of either Phe-121 or Phe-122 leads to decline in antithrombin-heparin binding affinity. Cofactor binding serpins are critically balanced to maintain its native metastability during its binding and transformation of conformational change (Figure 3).

5. Serpin Metastable Form

The metastable native state of serpins is thought to be like a kinetically trapped folding intermediate that is blocked by a very high kinetic barrier [24, 25]. The study of this kinetic trap provided an important link to understand structure-function relationships of serpins but the molecular basis by which this kinetic trap prevents the native serpin to form a more stable state is unknown [26]. It has been suggested that there are certain native interactions in the metastable form which drags it to get converted into a more stable form [24]. Studies have shown that the other stable conformation in the native serpin chain is the latent RCL-inserted form [17, 27]. For example the native form of a serpin, plasminogen activator inhibitor-1, readily gets transitioned into the latent form under physiological conditions with a half-life of 1-2 hours [28] and same happens in other serpins under mild denaturing conditions [29].

In serpins, when RCL is inserted into the A β-sheet, there occur a gradual decline in the free energy of the serpin and an increase in its stability [30–32]. Surprisingly, serpins also undergo a rise in thermostability when complexed with

| Table 1: Represents the Scissile bond in various serpins and their protease targets. Antithrombin is an efficient inhibitor of factor Xa, thrombin and factor Ixa. Residues flanking the P1-P1’ are also critical for protease multispecificity. |
|-----------------|---------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Clade; Serpin   | P4 | P3 | P2 | P1-P1’ | P2’ | P3’ | P4’ | Primary target          |
| A1; α1-PI       | A   | I   | P   | M-S   | I   | P   | P   | Neutrophil elastase     |
| A3; α1-ANT      | I   | T   | L   | L-S   | A   | L   | V   | Cathepsin G             |
| A4; kallistatin | K   | F   | F   | F-S   | A   | Q   | T   | Tissue kallikrein       |
| A5; PCI         | F   | T   | F   | R-S   | A   | R   | L   | Activated protein C     |
| A10; PZ         | I   | T   | A   | Y-S   | M   | P   | P   | fXa & fXla               |
| B1; MNEI        | A   | T   | F   | C-M   | L   | M   | P   | Neutrophil elastase     |
| B2; PAI-2       | M   | T   | G   | R-T   | G   | H   | G   | plasminogen activator   |
| B3; SCCA1       | G   | F   | G   | S-S   | P   | A   | S   | Cathepsin K, L & S      |
| B6; PI6         | M   | M   | M   | R-C   | A   | R   | F   | plasmin                 |
| C1; antithrombin III | I   | A   | G   | R-S   | L   | N   | P   | IIa & fXa                |
| D1; heparin cofactor II | F   | M   | P   | L-S   | T   | Q   | V   | IIa                      |
| E1; PAI-1       | V   | S   | A   | R-M   | A   | P   | E   | Plasminogen activator   |
| E2; protease nexin 1 | I   | L   | A   | R-S   | S   | P   | P   | Plasminogen activator   |
| F2; α2-antiplasmin | A   | M   | S   | R-M   | S   | L   | S   | Plasmin                 |
| G1; C1-inhibitor | S   | V   | A   | R-T   | L   | L   | V   | C1                       |
| I1; neuroserpin | A   | I   | S   | R-M   | A   | V   | L   | Plasmin & plasminogen activator |

without cleavage, the RCL has to pass around the β-turn linking strand s3C and s4C [10, 18].
### Table 2: Serpins and their known protease and nonprotease ligands.

| Serpin                          | Non protease ligands                                      | Protease target                                    |
|--------------------------------|----------------------------------------------------------|---------------------------------------------------|
| Antithrombin                   | Heparin, heparin sulfate                                  | Thrombin, factor Xa, factor IXa                     |
| Antichymotrypsin               | DNA, Aβ_{1-42}peptide                                      | Cathepsin G                                       |
| Alpha-1 Proteinase inhibitor   |                                                          | Neutrophil elastase                                |
| C1-Inhibitor                   | Heparin, collagen                                         | Cls of complement system                           |
| Headpin                        |                                                          | Lysosomal cathepsin                                |
| Heparin CofactorII             | Heparin, dermatan sulfate                                 | Thrombin                                           |
| HSP47                          | Collagen                                                 |                                                   |
| Kallistatin                    | Heparin                                                  | Tissue Kallikerin                                  |
| Maspin                         | Collagen                                                 |                                                   |
| MENT                           | DNA                                                      | Nuclear cysteine proteinase                         |
| Plasminogen Activator inhibitor-1| Heparin, heparin sulfate, vitronectin                     | tPA, uPA, thrombin, aPC                            |
| Protein C inhibitor            | Heparin, retinoic acid                                   | uPA, thrombin, aPC                                 |
| Protease nexin-1               | Heparin, collagen                                         | Thrombin uPA                                       |
| Thyroxine Binding Globulin     | Thyroxine, triiodothyronine                               |                                                   |
| Protein Z dependent protease inhibitors (ZPI)| Protein Z                                              | Factor Xa                                          |

**Figure 2:** Important domains in serpin conformations. Several regions are important in controlling and modulating serpin conformational changes. The Reactive Centre Loop is involved in protease recognition and conformational transformation as strand 4A after inhibition. The P15–P9 portion of the RCL is called the hinge region. The point of initial insertion of the RCL which is the breach region, located at the top of the A β-sheet. Near the center of A β-sheet is the shutter domain. The breach and shutter are two major regions that assist sheet opening and accept the conserved hinge of the RCL when it inserts. The gate region is composed of s3C and s4C strands which has been primarily observed by studies of the transition latency. The image was drawn in chimera using the PDB file of native antitrypsin conformation.

peptides analogous to the RCL [33]. This suggests that increased stability is a product of hydrogen bond formation and hydrophobic interactions made by the addition of a sixth strand to the A β-sheet as s4A. But the negative consequence of obtaining metastability is that serpins are vulnerable to mutations that can result in aberrant structural rearrangement into dysfunctional states with increased stability [34].

### 6. The Molecular Basis of Serpin Metastability

Native state of the serpin is dependent on nonideal interactions (Table 3) which imparts strain within the native fold that can be further alleviated by adopting alternative conformations [35]. Nonideal interactions include the presence of hydrophobic pockets [36, 37], overpacking of side-chains [38], and the burial of polar groups [39] and cavities in the hydrophobic core of the protein [40]. Molecular details of how such structural defects control the protein functions are yet to be elucidated. Native conformation regulates the inhibitory function of α-1 antitrypsin by controlling the rate of the conformational switch during complex formation with a target protease. Hence the conformational switch is driven by mobilization of unfavourable interactions in the native state into more favourable ones, such interactions seem to have control over conformational switch [41]. From fluorescence studies it has been identified that nonnative interactions were residing around the top of the A β-sheet and the F-helix [42, 43]. Some unfavourable interactions that are involved in maintaining the metastable state of antitrypsin are summarized in Table 3. The unfavourable interactions made by residues of the F-helix might play a crucial role in preventing incorrect folding in serpin [35, 44]. Lys-335 is suitably situated near the F-helix to assist in the sheet A opening where it forms critical interaction with Ile-169 and Leu-172, a reduction in the side chain of these residues...
results in increase in stability which contributes in the native strain. Polar-nonpolar interactions also contribute to native stability, Phe-189 interacts with Gly-164 and Thr-165 in the F-helix providing unfavourable interaction which contributes in native metastability [40].

Serpins make use of many conserved interactions which are distributed around the molecule to stay in the kinetic trap until a protease comes along and initiates further thermodynamically favourable conformational changes [44]. Decreasing the size of side chains in overpacked regions releases the native strain, and increasing the size of side chains in cavities stabilizes the native form, probably by providing better interactions with nearby residues. Likewise, filling exposed hydrophobic pockets by substituting larger residues also stabilizes the native state in antitrypsin [40]. Such unfavourable structural features are also found in other serpin proteins, like antichymotrypsin and antithrombin III, and the native strain in these serpins can also be relieved by compensating substitutions [45]. During protease inhibitor complex formation, unfavourable interactions in the native form are mobilized and transformed into more favourable ones [3]. These conformational changes result in the conversion of the metastable native form into a more stable conformation [46].

Figure 3: Conformational changes in cofactor (heparin) bound serpin (antithrombin) and residues involved in cofactor interaction. Heparin binding produces a series of conformational changes in antithrombin; extension of helix D by forming a 2 turn helix (P-helix) at the N-terminal end and a 1.5 turn extension of D-helix towards the C-terminal end. Moving of strand 3A and strand 5A and expulsion of reactive center loop leads to activated antithrombin. Given below are the basic residues in the heparin binding site that interact with the pentasaccharide are Lys-11 and Arg-13 in the N-terminal end; Arg-46 and Arg-47 in the A-helix; and Lys-114, Phe-121, Phe-122, Lys-125, and Arg-129 in the region of the D-helix. The figures were made by using antithrombin PDB (native 1E05; activated 1E03) files and swiss-prot PDB viewer.
Other types of loop-sheet interactions [47]. As a protein [3, 6]. Approximately mechanism required for their role as protease inhibitors fold and the thermodynamically driven β stable polymers owing to the metastability of their native strand in a pre-existing

Table 3: Unfavourable interactions that contribute to the metastability of the native antitrypsin. Nonideal interactions include the presence of hydrophobic pockets, overpacking of side-chains, the burial of polar groups, cavities in the hydrophobic core of the protein and polar nonpolar interactions [40]. Lys-335 is one of the residues in antitrypsin that has been shown to play a crucial role in conformational switch during the process of inhibition. Local strain due to Lys-335 interactions in the native state is critical for the inhibitory activity.

| Over packing of side chains | Polar-nonpolar interactions | Cavity filling mutations | Favourable interactions |
|-----------------------------|-----------------------------|-------------------------|------------------------|
| Lys-335                     | Phe-189—Gly-164 Gly164Val  | Native (Lys-335 is buried) |
| Ile-169                     | Thr-165-Val-161 Ala183Val   | Cleaved                  |
|                            | Thr-165-Ile-169             | Lys-335 forms salt bridge with Asp-171 |
| Leu-172                     | Leu-172-Asn-186 Thr114Phe   | Ile-169                  |
|                            | Lys-331-Val-333 Gly117Phe  | Lys-168-Glu-346 (salt bridge) |

7. Serpin Polymerization

The tendency of the RCL of serpins to become an additional strand in a pre-existing β-sheet also makes them prone to other types of loop-sheet interactions [47]. As a protein family, serpins are particularly prone to the formation of stable polymers owing to the metastability of their native fold and the thermodynamically driven β-sheet opening out mechanism required for their role as protease inhibitors [3, 6]. Approximately −32 kcal/mol energy is released by the incorporation of the reactive centre loop (RCL) of the serpin into the centre of its main β-sheet [48]. Figure 4 shows point mutation in some representative serpins that leads to dimerization, aggregation and polymerization.

Severe deficiency of the Z variant of α-1-antitrypsin (Glu342Lys) results from a conformational switch and forms a unique linkage between the reactive centre loop of one molecule and A β-sheet of a second [49]. This process of polymer formation was dependent on temperature and concentration, and the polymers that were formed had the appearance of “beads on a string” when seen by electron microscopy [49, 50]. Since this initial report, investigations have been concerned with the characterization and classification of clinically relevant mutations. Neurserpin is a member of the serine proteinase inhibitor (serpin) superfamily that is secreted from the growth cones of neurons and inhibits the enzyme tissue type plasminogen activator (tPA) [51]. Aberrant protein linkage in mutants of neurserpin causes intracerebral inclusions and dementia. Four different mutations of neurserpin (Ser49Pro, Ser52Arg, His338Arg and Gly392Glu) have been described in humans [52–54]. All four mutations cause the spontaneous formation of neurserpin polymers that are retained as inclusion (or Collins) bodies within neurons in the deeper layers of the cortex and the substantia nigra [35, 55]. It can be responsible for the occurrence of dementia, tremor, seizures, epilepsy and dysarthria that is present in different degrees depending on the harshness of the mutation involved. In heparin cofactor-II, there are two known polymerization variants which are Glu428Lys and Pro433Leu [56].

8. Polymeric Conformations in Serpin

Loop A sheet polymeric structure is characterised by the insertion of RCL of one serpin molecule into A β-sheet of another between strand three and five [57]. Initial evidence of this intermolecular linkage came from studies in which α-1 antitrypsin polymerization was hindered by incubation with peptides analogous to the RCL [49, 58] that was further supported by fluorescence energy transfer data [59]. In loop C sheet polymer, one of the strand of C β-sheet moves away to allow full insertion of the RCL and the position left vacant by s1C is filled by the RCL of second molecule [35]. This polymeric form is found in Mmalton variant of antitrypsin, antithrombin can also forms similar type of polymer when heated in the presence of citrate [60]. s7A polymer has only been shown in PAI-1, which is characterised by hydrogen bonding of the RCL of one molecule with six strand of the β-sheet A of the other, where donor RCL become the seventh stand of the acceptor molecule’s A β-sheet [61]. In disulfide linked polymeric form the RCL is not involved as a polymer formation domain as it does in other polymeric forms. Dimer α-1 antitrypsin has single cysteine residue located on the B β-sheet and this dimeric species goes on to form high order polymer. However, this disulfide-linked polymer has similar linear morphology to both loop A and C sheet as supported by electron microscopy [62].

9. Helix B Variants in the Shutter Region

The shutter region of serpins is comprised of a number of well-conserved residues that play a significant role in the maintenance of stability and function [35]. Mutations in shutter region allow the aberrant opening of the A-sheet, with the likelihood of the insertion into its lower half of the reactive loop of another molecule to give intermolecular linkage and polymerization of the serpin. Shutter region includes F-helix, B-helix, strand s3A and s5A of β-sheet A that plays an important role in stability and function in serpins [35]. Conserved helix B residues interact with the β-sheet A at the upper portion of the shutter region where RCL inserts as s4A. Helix B mutations in α-1-antichymotrypsin (Leu55Pro) and α-1-antitrypsin (Phe51Leu, Ser53Phe and Val55Pro) can cause lung (emphysema) and liver diseases (cirrhosis). Protein C-inhibitor (Ser52Phe and Ser54Leu) and antithrombin (Pro80Ser/Thr, Thr85Met/Lys, Cys95Arg and Leu99Phe) have mutations which can result in angioedema and thrombosis [5, 25, 35, 56]. Importance of strand 6B deformation and exposure of helix B in smooth insertion of the reactive centre loop during serpin inhibition was hypothesized recently and indicated that helix B exposure in variants may increase its polymerization propensity [63].
Figure 4: Point mutation in representative serpins that leads to latency, dimerization, aggregation and polymerization. Figure shows different serpin members like antithrombin (1e05), α-1 antitrypsin (2qug), neuroserpin (1jjo), antichymotrypsin (4caa), heparin cofactor-II (1jmj) and C1-inhibitor along with corresponding natural variant that gives rise to polymerization. Images were prepared by using Pymol visualization tool.

10. Accessible Surface Area and Stability Analysis of Serpin Variants

It is possible that the variants that contribute to serpin polymerization are deeply buried and introduce local destabilization. We took antithrombin, antitrypsin, antichymotrypsin, neuroserpin and heparin cofactor II as representative inhibitory serpins in which details of polymerization variants are known and did an analysis of burial and stability. Table 4 shows the positions of the serpin variants along with their ASA values. Analysis shows that in most cases the amino acid involved in the polymerization was completely buried in the native conformation. In the native state, antithrombin Pro-80, Thr-85, Leu-99, antitrypsin Phe-51, Ser-53 and Val-55
Table 4: Analysis of the residue burial and stability of natural variant of serpin involved in polymerization.

| Serpins                  | ASA\(^b\) (Native) | ΔΔG\(^c\) (kcal/mol) |
|--------------------------|---------------------|----------------------|
| Antithrombin-P80 S/TK\(^a\) | 9.0                | −0.97, −0.72         |
| Antithrombin-T85 M/K\(^a\) | 2.9                | −0.73, −3.04         |
| Antithrombin-C95R         | 9.3                | −1.33                |
| Antithrombin-L99F         | 1.1                | −1.03                |
| Antithrombin-N187D       | 9.6                | −1.92                |
| Antithrombin-F229L       | 1.5                | −0.92                |
| Antithrombin-A382T       | 28.0               | −0.33                |
| Antithrombin-G424R       | 2.5                | −1.30                |
| Antithrombin-P429L       | 12.7               | −0.18                |
| Antitrypsin-F51L         | 0.0                | −1.42                |
| Antitrypsin-S53F         | 0.0                | −0.42                |
| Antitrypsin-V55P         | 2.6                | −2.28                |
| Antitrypsin-E264V        | 5.2                | 0.47                 |
| Antitrypsin-E342T        | 6.9                | 1.02                 |
| Neuroserpin-S49P         | 0.0                | −1.19                |
| Neuroserpin-S52R         | 0.0                | −1.06                |
| Neuroserpin-H338R        | 0.0                | −1.37                |
| Neuroserpin-G392E        | 0.0                | −0.30                |
| Antichymotrypsin-L55P    | 1.6                | −2.17                |
| Antichymotrypsin-P228A   | 4.9                | −1.45                |
| Heparin Cofactor-II-E428K| 18.0               | −0.22                |

\(^{a}\)Two different variant at the same position.

\(^{b}\)Accessible Surface Area (ASA) values were determined from DSSP algorithm. The pdb codes used for the analysis are as follows: antithrombin (1t1f), antitrypsin (1qlp), neuroserpin (1jjo and 3fgq), antichymotrypsin (1yxa), and heparin cofactor-II (1jmj).

\(^{c}\)ΔΔG were determined for the variants by using Imutant 2.0 at pH 7.0 and 25°C, the values were determined by using the difference of ΔG between the wild-type and the polymerization variants mentioned in the table.

11. Conclusion

Serpins fold into structures that are metastable and employ a unique suicide substrate-like inhibitory mechanism to achieve stable state. Serpins make use of many conserved interactions like decreasing the size of side chains in overpacked regions, and increasing the size of cavities and filling of exposed hydrophobic pockets to release the native strain to convert from the native form to a cleaved inhibitory stable conformation. Due to its inhibition mechanism serpin are prone to conformational defects resulting in severe pathological disorders. Understanding the mechanism of polymer formation in serpins is confusing due to availability of several models and also due to the lack of crystal structures of natural variants. Identifying specific domains and interactions in serpin that contribute to inhibition and polymerization mechanism is important. Helix B region is a mutation hotspot in serpin that leads to polymerization due to deep burial, decreased stability and its involvement in RCL translocation.

Acknowledgments

This research was supported by grants from Department of Biotechnology and University Grant Commission, Government of India. P. Singh is supported by a grant from Rajiv Gandhi National Fellowship. A. Naseem is supported by an INSPIRE fellowship from Department of Science and Technology, Government of India.

References

[1] R. W. Carrell, P. A. Pemberton, and D. R. Boswell, “The serpins: evolution and adaptation in a family of protease inhibitors,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 52, pp. 527–535, 1987.
[2] P. G. W. Gettins, “Keeping the serpin machine running smoothly,” Genome Research, vol. 10, no. 12, pp. 1833–1835, 2000.
[3] J. A. Huntington, R. J. Read, and R. W. Carrell, “Structure of a serpin-protease complex shows inhibition by deformation,” Nature, vol. 407, no. 6806, pp. 923–926, 2000.
[4] P. A. Patston, “Serpins and other serine protease inhibitors,” Immunology Today, vol. 21, no. 7, p. 354, 2000.
[5] J. Potempa, E. Korzus, and J. Travis, “The serpin superfamily of proteinase inhibitors: structure, function, and regulation,” Journal of Biological Chemistry, vol. 269, no. 23, pp. 15957–15960, 1994.
[6] P. G. W. Gettins, “Serpin structure, mechanism, and function,” Chemical Reviews, vol. 102, no. 12, pp. 4751–4804, 2002.
[7] J. A. Irving, R. N. Pike, A. M. Lesk, and J. C. Whisstock, “Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function,” Genome Research, vol. 10, no. 12, pp. 1845–1864, 2000.
[8] G. A. Silverman, P. I. Bird, R. W. Carrell et al., “The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 33293–33296, 2001.
[9] A. J. Horvath, J. A. Irving, J. Rossjohn et al., “The murine orthologue of human antichymotrypsin: a structural paradigm
for clade A3 serpins,” *Journal of Biological Chemistry*, vol. 280, no. 52, pp. 43168–43178, 2005.

[10] J. C. Whistock, R. Skinner, R. W. Carrell, and A. M. Lesk, “Conformational changes in serpins: I. The native and cleaved conformations of α-antitrypsin,” *Journal of Molecular Biology*, vol. 295, no. 3, pp. 651–665, 2000.

[11] D. A. Lawrence, S. T. Olson, S. Palaniappan, and D. Ginsburg, “Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition,” *Journal of Biological Chemistry*, vol. 269, no. 44, pp. 27675–27682, 1994.

[12] W. S. W. Chang, M. R. Wardell, D. A. Lomas, and R. W. Carrell, “Probing serpin reactive-loop conformations by proteolytic cleavage,” *Biochemical Journal*, vol. 314, no. 2, pp. 647–652, 1996.

[13] R. W. Carrell, P. E. Stein, G. Fermi, and M. R. Wardell, “Biological implications of a 3 Å structure of dimeric antithrombin,” *Structure*, vol. 2, no. 4, pp. 257–270, 1994.

[14] J. O. Jeppson, “Amino acid substitution Glu leads to Lys alpha1-antitrypsin,” *European Federation of Biological Society Letters*, vol. 65, no. 2, pp. 195–197, 1976.

[15] P. E. Stein and R. W. Carrell, “What do dysfunctional serpins tell us about molecular mobility and disease?” *Nature Structural Biology*, vol. 2, no. 2, pp. 96–113, 1995.

[16] M. M. Krem and E. Di Cera, “Conserved Ser residues, the shutter region, and speciation in serpin evolution,” *Journal of Biological Chemistry*, vol. 278, no. 39, pp. 37810–37814, 2003.

[17] J. Mottonen, A. Strand, J. Symersky et al., “Structural basis of latency in plasminogen activator inhibitor-1,” *Nature*, vol. 355, no. 6357, pp. 270–273, 1992.

[18] M. A. Dunstone, W. Dai, J. C. Whistock et al., “Cleaved antitrypsin polymers at atomic resolution,” *Protein Science*, vol. 9, no. 2, pp. 417–420, 2000.

[19] P. A. Patston, F. C. Church, and S. T. Olson, “Serpin-ligand interactions,” *Methods*, vol. 32, no. 2, pp. 93–109, 2004.

[20] A. Jayakumar, Y. Kang, M. J. Frederick et al., “Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis,” *Archives of Biochemistry and Biophysics*, vol. 409, no. 2, pp. 367–374, 2003.

[21] M. C. Naski, D. A. Lawrence, D. F. Mosher, T. J. Podor, and D. Ginsburg, “Kinetics of inactivation of α-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin,” *Journal of Biological Chemistry*, vol. 268, no. 17, pp. 12367–12372, 1993.

[22] M. A. Jairajpuri, A. Lu, and S. C. Bock, “Elimination of P1 arginine 393 interaction with underlying glutamic acid 255 partially activates antithrombin III for thrombin inhibition but not factor Xa inhibition,” *Journal of Biological Chemistry*, vol. 277, no. 27, pp. 24460–24465, 2002.

[23] M. A. Jairajpuri, A. Lu, U. Desai, S. T. Olson, I. Bjork, and S. C. Bock, “Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation,” *Journal of Biological Chemistry*, vol. 278, no. 18, pp. 15941–15950, 2003.

[24] R. W. Carrell and P. E. Stein, “The biostuctural pathology of the serpins: critical function of sheet opening mechanism,” *Biological Chemistry Hoppe-Seyler*, vol. 377, no. 1, pp. 1–17, 1996.

[25] J. C. Whistock and S. P. Bottomley, “Molecular gymnastics: serpin structure, folding and misfolding,” *Current Opinion in Structural Biology*, vol. 16, no. 6, pp. 761–768, 2006.

[26] H. Im, M. S. Woo, K. Y. Hwang, and M. H. Yu, “Interactions causing the kinetic trap in serpin protein folding,” *Journal of Biological Chemistry*, vol. 277, no. 48, pp. 46347–46354, 2002.

[27] E. Marszal and A. Shrike, “Serpin crystal structure and serpin polymer structure,” *Archives of Biochemistry and Biophysics*, vol. 453, no. 1, pp. 123–129, 2006.

[28] C. M. Hekman and D. J. Loskutoff, “Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants,” *Journal of Biological Chemistry*, vol. 260, no. 21, pp. 11581–11587, 1985.

[29] R. W. Carrell, J. A. Huntington, A. Mushunje, and A. Zhou, “The conformational basis of thrombin,” *Thrombosis and Haemostasis*, vol. 86, no. 1, pp. 14–22, 2001.

[30] H. Tonic Wright and M. A. Blajchman, “Proteolytically cleaved mutant antithrombin-Hamilton has high stability to denaturation characteristic of wild type inhibitor serpins,” *FEBS Letters*, vol. 348, no. 1, pp. 14–16, 1994.

[31] M. Yamasaki, Y. Mikami, and M. B. Hirose, “Loop-inserted and thermostabilized structure of P1-P1′ cleaved ovalbumin mutant R339I,” *Journal of Molecular Biology*, vol. 315, no. 2, pp. 113–120, 2002.

[32] P. Gettins and B. Harten, “Properties of thrombin- and elastase-modified human antithrombin III,” *Biochemistry*, vol. 27, no. 10, pp. 3634–3639, 1988.

[33] A. J. Schulze, U. Baumann, S. Knof, E. Jaeger, R. Huber, and C. B. Laurell, “Structural transition of α-antitrypsin by a peptide sequentially similar to B-strand s4A,” *European Journal of Biochemistry*, vol. 194, no. 1, pp. 51–56, 1990.

[34] T. R. Dafforn, R. N. Pike, and S. P. Bottomley, “Physical characterization of serpin conformations,” *Methods*, vol. 32, no. 2, pp. 150–158, 2004.

[35] G. L. Devlin and S. P. Bottomley, “A protein family under ‘stress’—serpin stability, folding and misfolding,” *Frontiers in Bioscience*, vol. 10, no. 1, pp. 288–299, 2005.

[36] E. J. Seo, H. Im, J. S. Maeng, K. E. Kim, and M. H. Yu, “Distribution of the native strain in human α-antitrypsin and its association with protease inhibitor function,” *Journal of Biological Chemistry*, vol. 275, no. 22, pp. 16904–16909, 2000.

[37] J. L. Sohl, S. S. Jaswal, and D. A. Agard, “Unfolded conformations of α-lytic protease are more stable than its native state,” *Nature*, vol. 395, no. 6704, pp. 817–819, 1998.

[38] K. N. Lee, S. D. Park, and M. H. Yu, “Probing the native strain in α-antitrypsin,” *Nature Structural Biology*, vol. 3, no. 6, pp. 497–500, 1996.

[39] S. E. Ryu, H. J. Choi, K. S. Kwon, K. N. Lee, and M. H. Yu, “The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved α-antitrypsin in 2.7 Å,” *Structure*, vol. 4, no. 10, pp. 1181–1192, 1996.

[40] H. Im, E. J. Seo, and M. H. Yu, “Metastability in the inhibitory mechanism of human α-antitrypsin,” *Journal of Biological Chemistry*, vol. 274, no. 16, pp. 11072–11077, 1999.

[41] K. N. Lee, C. S. Lee, W. C. Tae, K. W. Jackson, V. J. Christiansen, and P. A. McKee, “Cross-linking of wild-type and mutant α-antiplasmins to by activated factor XIII and by a tissue transglutaminase,” *Journal of Biological Chemistry*, vol. 275, no. 48, pp. 37382–37389, 2000.

[42] D. J. Tew and S. P. Bottomley, “Probing the equilibrium denaturation of the serpin α-antitrypsin with single tryptophan mutants; Evidence for structure in the urea unfolded state,” *Journal of Molecular Biology*, vol. 313, no. 5, pp. 1161–1169, 2001.

[43] L. D. Cabrita, J. C. Whistock, and S. P. Bottomley, “Probing the role of the F-helix in serpin stability through a single tryptophan substitution,” *Biochemistry*, vol. 41, no. 14, pp. 4575–4581, 2002.
[44] L. D. Cabrita and S. P. Bottomley, “How do proteins avoid becoming too stable? Biophysical studies into metastable proteins,” *European Biophysics Journal*, vol. 33, no. 2, pp. 83–88, 2004.

[45] H. Im, M. J. Ryu, and M. H. Yu, “Engineering thermostability in serine protease inhibitors,” *Protein Engineering, Design and Selection*, vol. 17, no. 4, pp. 325–331, 2004.

[46] M. Bruch, V. Weiss, and J. Engel, “Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites,” *Journal of Biological Chemistry*, vol. 263, no. 32, pp. 16626–16630, 1988.

[47] K. E. Pedersen, A. P. Einholm, A. Christensen et al., “Plasminogen activator inhibitor-1 polymers, induced by inactivating amphipathic organochemical ligands,” *Biochemical Journal*, vol. 372, no. 3, pp. 747–755, 2003.

[48] H. Im and M. H. Yu, “Role of Lys335 in the metastability and function of inhibitory serpins,” *Protein Science*, vol. 9, no. 5, pp. 934–941, 2000.

[49] D. A. Lomas, D. L. Evans, J. T. Finch, and R. W. Carrell, “The mechanism of Zα-antitrypsin accumulation in the liver,” *Nature*, vol. 357, no. 6379, pp. 605–607, 1992.

[50] D. A. Lomas, D. L. Evans, C. Upton, G. McFadden, and R. W. Carrell, “Inhibition of plasmin, urokinase, tissue plasminogen activator, and C(1S) by a myxoma virus serine proteinase inhibitor,” *Journal of Biological Chemistry*, vol. 268, no. 1, pp. 516–521, 1993.

[51] E. Miranda and D. A. Lomas, “Neuroserpin: a serpin to think about,” *Cellular and Molecular Life Sciences*, vol. 63, no. 6, pp. 709–722, 2006.

[52] R. L. Davis, A. E. Shrimpton, P. D. Holohan et al., “Familial dementia caused by polymerization of mutant neuroserpin,” *Nature*, vol. 401, no. 6751, pp. 376–379, 1999.

[53] R. L. Davis, A. E. Shrimpton, R. W. Carrell et al., “Association between conformational mutations in neuroserpin and onset and severity of dementia,” *Lancet*, vol. 359, no. 9325, pp. 2242–2247, 2002.

[54] T. Nakagawa, T. Kubota, M. Kabuto et al., “Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors,” *Journal of Neurosurgery*, vol. 81, no. 1, pp. 69–77, 1994.

[55] M. A. Dunstone, W. Dai, J. C. Whisstock et al., “Cleaved antitrypsin polymers at atomic resolution,” *Protein Science*, vol. 9, no. 2, pp. 417–420, 2000.

[56] B. Gooptu and D. A. Lomas, “Conformational pathology of the serpins: themes, variations, and therapeutic strategies,” *Annual Review of Biochemistry*, vol. 78, pp. 147–176, 2009.

[57] D. A. Lomas, P. R. Elliott, W. S. W. Chang, M. R. Wardell, and R. W. Carrell, “Preparation and characterization of latent α-antitrypsin,” *Journal of Biological Chemistry*, vol. 270, no. 10, pp. 5282–5288, 1995.

[58] A. E. Mast, J. J. Enghild, and G. Salvesen, “Conformation of the reactive site loop of α-proteinase inhibitor probed by limited proteolysis,” *Biochemistry*, vol. 31, no. 10, pp. 2720–2728, 1992.

[59] P. Sivasothy, T. R. Dafforn, P. G. W. Gettins, and D. A. Lomas, “Pathogenic α-antitrypsin polymers are formed by reactive loop-β-sheet A linkage,” *Journal of Biological Chemistry*, vol. 275, no. 43, pp. 33663–33668, 2000.

[60] H. Koloczek, A. Banbula, G. S. Salvesen, and J. Potempa, “Serpin α-proteinase inhibitor probed by intrinsic tryptophan fluorescence spectroscopy,” *Protein Science*, vol. 5, no. 11, pp. 2226–2235, 1996.

[61] A. M. Sharp, P. E. Stein, N. S. Pannu et al., “The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion,” *Structure*, vol. 7, no. 2, pp. 111–118, 1999.

[62] E. Marszal, D. Danino, and A. Shrake, “A novel mode of polymerization of α-proteinase inhibitor,” *Journal of Biological Chemistry*, vol. 278, no. 22, pp. 19611–19618, 2003.

[63] P. Singh and M. A. Jairajpuri, “Strand 6B deformation and residues exposure towards N-terminal end of helix B during proteinase inhibition by Serpins,” *Bioinformation*, vol. 5, no. 8, pp. 315–319, 2011.
